The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2023 | The changing role of chemotherapy in the treatment of various subtypes of NHL
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses the changing role of chemotherapy in the treatment of various subtypes of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Dr Sureda explains the growing importance of novel cellular and immune therapies, including CAR-T cells and antibodies, and further highlights how the treatment of DLBCL is likely to change with the use of these agents in the first-line and relapsed settings. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
